^
Association details:
| Biomarker: | ZNF689 underexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ZNF689 promotes homologous recombination via NBS1 ubiquitination and its loss confers sensitivity to PARP inhibition in triple-negative breast cancer
Published date:
12/02/2023
Excerpt:
Importantly, low ZNF689 expression was associated with a favorable response to PARP inhibitors in TNBC patients….These findings suggest ZNF689 as a promising therapeutic target for enhancing the effectiveness of PARP inhibitors in TNBC patients.